olokizumab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
olokizumab

GtoPdb Ligand ID: 11601

Synonyms: CDP 6038 | CDP-6038 | CDP6038

Compound class: Antibody

Comment: Olokizumab (CDP 6038) is a clinical stage anti-IL-6 monoclonal antibody [3], that was designed for potential to treat autoimmune diseases. The antibody blocks assembly of the hexameric IL-6/IL-6 α-receptor/gp130 (IL6ST) complex that is required for signal transduction.

References
1. Genovese MC, Durez P, Fleischmann R, Tanaka Y, Furst D, Yamanaka H, Korneva E, Vasyutin I, Takeuchi T. (2021) Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. Eur J Rheumatol, 8 (3): 120-129. [PMID:34101570]
2. Kretsos K, Golor G, Jullion A, Hickling M, McCabe S, Shaw S, Jose J, Oliver R. (2014) Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev, 3 (5): 388-95. [PMID:27129012]
3. Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S et al.. (2014) Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs, 6 (3): 774-82. [PMID:24670876]
4. (2018) Erratum. Mod Rheumatol, 28 (5): 911-912. [PMID:29869893]

References

1. Genovese MC, Durez P, Fleischmann R, Tanaka Y, Furst D, Yamanaka H, Korneva E, Vasyutin I, Takeuchi T. (2021)
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies.
Eur J Rheumatol, 8 (3): 120-129. [PMID:34101570]

2. Kretsos K, Golor G, Jullion A, Hickling M, McCabe S, Shaw S, Jose J, Oliver R. (2014)
Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study.
Clin Pharmacol Drug Dev, 3 (5): 388-95. [PMID:27129012]

3. Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S et al.. (2014)
Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.
MAbs, 6 (3): 774-82. [PMID:24670876]

4. (2018)
Erratum.
Mod Rheumatol, 28 (5): 911-912. [PMID:29869893]